Skip to main content
Top
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Cross-sectional increase of adherence to multidisciplinary tumor board decisions

Authors: S. Hollunder, U. Herrlinger, M. Zipfel, J. Schmolders, V. Janzen, T. Thiesler, E. Güresir, A. Schröck, F. Far, T. Pietsch, D. Pantelis, D. Thomas, S. Vornholt, N. Ernstmann, T. Manser, M. Neumann, B. Funke, I. G. H. Schmidt-Wolf

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Cancer research has made great progress in the recent years. With the increasing number of options in diagnosis and therapy the implementation of tumorboards (TUBs) has become standard procedure in the treatment of cancer patients. Adherence tests on tumor board decisions are intended to enable quality assurance and enhancement for work in tumor boards in order to continuously optimize treatment options for cancer patients.

Methods

Subject of this study was the adherence of the recommendations made in three of 14 tumorboards, which take place weekly in the Center for Integrated Oncology (CIO) at the University Hospital Bonn. In total, therapy recommendations of 3815 patient cases were checked on their implementation. A classification into four groups has been made according to the degree of implementation. A second classification followed regarding the reasons for differences between the recommendation and the therapy which the patient actually received.

Results

The study showed that 80.1% of all recommendations in the three TUBs were implemented. 8.3% of all recommendations showed a deviance. Most important reasons for the deviances were patient wish (36.5%), patient death (26%) and doctoral decision, due to the patient’s comorbidities or side effects of the treatment (24.1%).Interestingly, deviance in all three tumor boards in total significantly decreased over time.

Conclusions

Aim of the study was to clarify the use of tumor boards and find approaches to make them more efficient. Based on the results efficiency might be optimized by increased consideration of patients` preferences, improved presentation of patient-related data, more detailed documentation and further structuring of the tumor board meetings.
Literature
1.
go back to reference Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet (London, England). 1995;345(8960):1265–70.CrossRef Sainsbury R, Haward B, Rider L, Johnston C, Round C. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet (London, England). 1995;345(8960):1265–70.CrossRef
3.
go back to reference McAvoy B. Optimising cancer care in Australia. Aust Fam Physician. 2003;32(5):369–72.PubMed McAvoy B. Optimising cancer care in Australia. Aust Fam Physician. 2003;32(5):369–72.PubMed
4.
5.
go back to reference Strohschneider T. Opening address by Prof. Dr. Siewert at the 23rd Congress of the German Cancer Society 8 June 1998 in Berlin "Oncology in the tension field between reality and vision". Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 70((6):suppl):156. Strohschneider T. Opening address by Prof. Dr. Siewert at the 23rd Congress of the German Cancer Society 8 June 1998 in Berlin "Oncology in the tension field between reality and vision". Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 70((6):suppl):156.
8.
go back to reference Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven V, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C. The brain tumor board: lessons to be learned from an interdisciplinary conference. Oncol Res and Treat. 2005;28(1):22–6.CrossRef Lutterbach J, Pagenstecher A, Spreer J, Hetzel A, Velthoven V, Nikkhah G, Frommhold H, Volk B, Schumacher M, Lücking C, Zentner J, Ostertag C. The brain tumor board: lessons to be learned from an interdisciplinary conference. Oncol Res and Treat. 2005;28(1):22–6.CrossRef
10.
go back to reference Taylor C, Munro A, Glynne Jones R, Griffith C, Trevatt P, Richards M, Ramirez A. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340(mar23 2):c951.CrossRef Taylor C, Munro A, Glynne Jones R, Griffith C, Trevatt P, Richards M, Ramirez A. Multidisciplinary team working in cancer: what is the evidence? BMJ. 2010;340(mar23 2):c951.CrossRef
11.
go back to reference Scher K, Tisnado d RD, Adams J, Ko C, Malin J, Ganz P, Kahn K. Physician and practice characteristics influencing tumor board attendance: results from the provider survey of the Los Angeles Women’s health study. J Oncol Pract. 2011;7(2):103–10 doi:10:10.1200/jop.2010.000085.CrossRef Scher K, Tisnado d RD, Adams J, Ko C, Malin J, Ganz P, Kahn K. Physician and practice characteristics influencing tumor board attendance: results from the provider survey of the Los Angeles Women’s health study. J Oncol Pract. 2011;7(2):103–10 doi:10:10.1200/jop.2010.000085.CrossRef
15.
go back to reference Oberndorfer S. Tumorboards stellen sich vor: Neuroonkologisches Tumorboard. Tumorboard. 2014;3(1):21–3. Oberndorfer S. Tumorboards stellen sich vor: Neuroonkologisches Tumorboard. Tumorboard. 2014;3(1):21–3.
Metadata
Title
Cross-sectional increase of adherence to multidisciplinary tumor board decisions
Authors
S. Hollunder
U. Herrlinger
M. Zipfel
J. Schmolders
V. Janzen
T. Thiesler
E. Güresir
A. Schröck
F. Far
T. Pietsch
D. Pantelis
D. Thomas
S. Vornholt
N. Ernstmann
T. Manser
M. Neumann
B. Funke
I. G. H. Schmidt-Wolf
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4841-4

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine